CytoNiche

a Tsinghua Medical School spin-off whose microcarriers carried the first stem-cell drug approved in China (2025) after partner 铂生卓越 switched its phase III MSC process from 2D to 3D in 2022; closed a B+ round of several hundred million RMB (2025) from Beijing municipal funds, ICBC and CICC.

Country
China
Growth-stage 3D TableTrix
Coverage
CNEUUS
consumables✓✓✓
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
Fundingraised total funding of approximately $94.9M across multiple rounds, including a series B+ round of several hundred million RMB and a Series B round of approximately $47.5Mbiospectrumasia.com · vcbeathealth.com
Capacityannual output of 300 kg for microcarriers and 300,000 bottles for culture medium additivesvcbeathealth.com
CertificationGMP-grade microcarriers registered under Type IV & Type II DMF (U.S. FDA)en.cytoniche.com
Regulatory approval3D FloTrix platform technology supported the approval of China's first stem cell drug (Amimestrocel Injection) on January 2, 2025en.cytoniche.com · synapse.patsnap.com · vcbeathealth.com
Production siteGMP production platform of 6,000 square meters, including a 4,000 square meter Tianjin cGMP production center and a research and development platform of nearly 7,000 square metersbiospectrumasia.com · vcbeathealth.com
Headcountreported between 4 and 7 employees as of 2026 medium confidencecaplight.com

Independent sources: biospectrumasia.com · caplight.com · synapse.patsnap.com · vcbeathealth.com

Technologies
NameClusterRisk
Microcarriers for adherent cell culturesconsumablesLow→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.